Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT07349160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to better fight cancer. The study will enroll 36 participants and primarily look at safety, while also checking if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metabolically armed tumor-infiltrating lymphocytes (Meta10-TIL cells)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 36 participants, so it is too soon to know if it will be safe or effective. The treatment involves infusing modified immune cells, which may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100000, China
Contact
Contact
Contact Phone: •••-•••-••••
Contact